New combo therapy targets hard-to-treat pancreatic cancer
NCT ID NCT03301805
First seen Apr 22, 2026 · Last updated Apr 26, 2026 · Updated 1 time
Summary
This study tests a new oral drug called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 adults with advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe dose and see if the combination shrinks tumors. Participants will be monitored for side effects and treatment response over several cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.